Skip to main content
. 2021 Jan 1;18(1):137–149. doi: 10.7150/ijms.48393

Figure 6.

Figure 6

Immunoblot (IB) analysis of cell cycle regulator (A) cyclin D1 expression and (B) cyclin-dependent kinase inhibitor p21 expression comparing Dasatinib combined with Torin-2 (D+T) or Rapamycin (D+R) treatment in neuroblastoma cell line Kelly and IMR-32. C: Vehicle (DMSO)-treated control cells. GAPDH served as loading control. Protein expression corrected to GAPDH is indicated in numbers below bands. Cells were seeded 24 h before drug treatment with a combination of Dasatinib with Torin-2 or Rapamycin, respectively. Drug concentration used for the combination treatment in Kelly [D+T = 1.5 μM + 9 nM; D+R = 5 μM + 2 μM;] and IMR-32 [D+T = 1 μM + 6 nM; D+R = 0.05 μM + 0.13 μM]. Cells were harvested 24 h (cyclin D1), respectively 72 h (p21) after treatment.